BA
CLSD

BlackRock Advisors’s Clearside Biomedical CLSD Stock Holding History

BlackRock Advisors’s Portfolio CLSD Stock Details CLSD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$25K Buy
184
+178
+2,967% +$44.7K ﹤0.01% 3412
2016
Q3 		$2K Buy
+6
New +$735 ﹤0.01% 3682

Other funds holding CLSD

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BlackRock Advisors's CLSD Position: Q4 2016 in Review

BlackRock Advisors increased its Clearside Biomedical (CLSD) stake by 2,967% in Q4 2016, buying an estimated $44.7K and bringing the position to 184 shares worth $25K. The position accounts for ﹤0.01% of the portfolio, ranked #3412.

BlackRock Advisors first reported a position in CLSD in Q3 2016 and has held it in 2 quarters since. 62 funds tracked by Wall St. Rank hold CLSD as of Q4 2016.

  • BlackRock Advisors held 184 shares of Clearside Biomedical worth $25K as of Q4 2016.
  • BlackRock Advisors bought 178 Clearside Biomedical shares in Q4 2016, an estimated $44.7K.
  • Clearside Biomedical made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #3412 holding.
  • BlackRock Advisors first reported a position in Clearside Biomedical in Q3 2016 and has held it in 2 quarters since.
  • 62 funds tracked by Wall St. Rank held Clearside Biomedical as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.